Liraglutide Impurity B [Glu]17 includes a glutamate substitution at position 17, altering local charge and helix stability. Researchers compare its folding, receptor-binding affinity, and solubility to the parent peptide. Its behavior informs degradation pathways and sequence sensitivity. Applications include impurity profiling, structural mapping, and ligand-optimization work.
CAT No: Z10-101-204
Synonyms/Alias:H-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Pal-γ-Glu)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH; Glu(17)-Liraglutide
Liraglutide Impurity B [Glu]17 is a structurally distinct carbohydrate compound recognized for its role as a process-related impurity in the synthesis and analysis of liraglutide, a glucagon-like peptide-1 (GLP-1) analog. Characterized by the substitution of glutamic acid at the 17th position, this impurity serves as a critical reference material in pharmaceutical research and quality control. Its defined structure and close resemblance to the parent compound make it invaluable for analytical method development, stability assessments, and impurity profiling. The availability of Liraglutide Impurity B [Glu]17 enables researchers and manufacturers to better understand the behaviors and characteristics of related substances that may arise during peptide synthesis, thus supporting comprehensive product characterization and ensuring the reliability of analytical results.
Analytical Method Validation: Liraglutide Impurity B [Glu]17 is widely utilized in the validation of high-performance liquid chromatography (HPLC) and mass spectrometry (MS) methods tailored for peptide drug analysis. By incorporating this impurity as a reference standard, laboratories can rigorously assess the specificity, sensitivity, and accuracy of their analytical protocols. Its presence allows for the identification and quantification of structurally similar impurities, ensuring that the developed methods are robust and reliable for routine quality control. The use of this impurity in method validation ultimately contributes to the reproducibility of analytical data and the consistency of peptide drug products.
Impurity Profiling in Drug Development: During the development and manufacturing of liraglutide and related peptides, the formation of minor impurities such as [Glu]17 is inevitable. Employing Liraglutide Impurity B [Glu]17 as a reference material facilitates comprehensive impurity profiling, enabling researchers to detect, identify, and monitor trace levels of process-related substances. This practice is essential for understanding the synthetic pathway, optimizing purification processes, and minimizing the presence of undesired byproducts. Accurate impurity profiling not only supports regulatory submissions but also enhances the overall quality of the final pharmaceutical product.
Stability Studies: The inclusion of [Glu]17 impurity in stability studies provides valuable insights into the degradation pathways and potential transformation products of liraglutide formulations. By subjecting samples containing this impurity to various stress conditions—such as temperature, humidity, and light exposure—scientists can evaluate the chemical stability and shelf-life of peptide drugs. Monitoring the behavior of Liraglutide Impurity B [Glu]17 under these conditions assists in predicting product performance over time and informs the selection of optimal storage and packaging solutions.
Reference Standard for Calibration: Laboratories rely on well-characterized reference standards like Liraglutide Impurity B [Glu]17 for the calibration of analytical instruments used in peptide quantification. Accurate calibration with this impurity ensures that instruments provide precise and reproducible measurements, which is crucial for both research and routine quality control. The use of such standards supports the establishment of reliable calibration curves, facilitates the comparison of results across different laboratories, and underpins the integrity of analytical data generated throughout the drug development lifecycle.
Research on Peptide Modifications: The structural features of [Glu]17 offer a unique model for studying the effects of specific amino acid substitutions on peptide function and stability. Researchers investigating peptide modification strategies can utilize this impurity to explore how alterations at defined positions influence biological activity, folding, and resistance to enzymatic degradation. Insights gained from such studies inform the rational design of improved peptide therapeutics and contribute to the advancement of peptide science as a whole.
In summary, Liraglutide Impurity B [Glu]17 plays a pivotal role across multiple facets of peptide drug research and development. Its applications in analytical method validation, impurity profiling, stability testing, instrument calibration, and peptide modification studies underscore its value as an essential tool for scientists and manufacturers. By enabling precise analysis and deeper understanding of peptide impurities, this compound helps drive innovation and quality in the field of pharmaceutical research.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More